Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform

Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform

Conditions: Metastatic Cancer; NSCLC Stage IV; Non-small Cell Lung Cancer Stage IV; Small Cell Lung Cancer Metastatic; Solid Tumor; Clear Cell Renal Cell Carcinoma Metastatic; Urothelial Carcinoma Bladder; Cutaneous Malignant Melanoma; Castration-resistant Prostate Cancer; Prostate Cancer Metastatic; TNBC – Triple-Negative Breast Cancer; Breast Cancer Stage IV; Colon Cancer Stage IV; MSI-H Cancer; Cervical Cancer Stage IV; Endometrial Cancer Stage IV; Mismatch Repair-Deficient Endometrial Endometrioid Adenocarcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Tissue Collection
Sponsors: Mayo Clinic
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 6, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments